The Latest Analyst Ratings For Arcellx
Ratings for Arcellx (NASDAQ:ACLX) were provided by 8 analysts in the past three months, showcasing a mix of…
Expert Ratings For Arcellx
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Arcellx (NASDAQ:ACLX)…
Analyst Expectations For Arcellx’s Future
During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish…
Peering Into Arcellx’s Recent Short Interest
Arcellx’s (NYSE:ACLX) short percent of float has risen 6.28% since its last report. The company recently reported that…
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List – Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction List.
Needham Maintains Buy Rating for Arcellx: Here’s What You Need To Know
Needham has decided to maintain its Buy rating of Arcellx (NASDAQ:ACLX) and raise its price target from $65.00…
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.
Blood Cancer Player Arcellx’s Lead Product Exceeds Expectations, Analysts Say
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or
Where Arcellx Stands With Analysts
Within the last quarter, Arcellx (NASDAQ:ACLX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Arcellx Announces Continued Robust Long-Term Responses From Its CART-ddBCMA Phase 1 Expansion Trial In Patients With Relapsed Or Refractory Multiple Myeloma At ASH
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months –-- The estimated median progression free